Regulus Therapeutics Inc.
RGLS
Rank in Stocks
#17336
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
-88.86%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)
Category
Healthcare
Stock split history for Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Inc. stock (symbol: RGLS) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 19, 2026.
One RGLS share bought prior to Oct 19, 2026 would equal to 0 RGLS shares today.
The most recent stock split occurred on Oct 19, 2026.
One RGLS share bought prior to Oct 19, 2026 would equal to 0 RGLS shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
